ロード中...
Update on PARP Inhibitors in Breast Cancer
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat...
保存先:
| 出版年: | Curr Treat Options Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7430202/ https://ncbi.nlm.nih.gov/pubmed/29644491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0540-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|